Photodynamic therapy of cutataneous lymphoma using 5-aminolevulinic acid topical application

Dermatologic Surgery

Volumn 26, Issue 8, 2000, Pages 765-770

  Orenstein, Arie ^a   Haik, Joseph ^a   Tamir, Jeremy ^a   Winkler, Eyal ^a   Trau, Henry ^a   Malik, Zvi ^b   Kostenich, Genady ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; FLUPREDNIDENE ACETATE; PROTOPORPHYRIN; PHOTOSENSITIZING AGENT;

ADULT; AGED; ARTICLE; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; ESTHETICS; FLUORESCENCE; HUMAN; MALE; MYCOSIS FUNGOIDES; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; T CELL LYMPHOMA; TREATMENT OUTCOME; ABDOMEN; CUTANEOUS T CELL LYMPHOMA; METABOLISM; PATHOLOGY; PHOTOCHEMOTHERAPY; SKIN DISEASE; SKIN TUMOR; SPECTROFLUOROMETRY; TOPICAL DRUG ADMINISTRATION;

ABDOMEN; ADMINISTRATION, TOPICAL; ADULT; AGED; AMINOLEVULINIC ACID; FACIAL DERMATOSES; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MYCOSIS FUNGOIDES; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROTOPORPHYRINS; SKIN NEOPLASMS; SPECTROMETRY, FLUORESCENCE;

EID: 0033867468     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4725.2000.00056.x     Document Type: Article

References (24)

1. Hoppe RT. The management of mycosis fungoides at Stanford -standard and innovative treatment programs. Leukemia 1991; 5(suppl 1):46-8.
2. Hoppe RT, Wood GS, Abel EA. Mycosis fungoides and the Sezary syndrome: pathology, staging, and treatment. Curr Probl Cancer 1990;14:293-371.
3. Abel EA, Sendagorta E, Hoppe RT, Hu CH. PUVA treatment of erythrodermic and plaque-type mycosis fungoides. Ten-year follow-up study. Arch Dermatol 1987;123:897-901.
4. Reddy VB, Ramsay D, Garcia JA, Kamino H. Atypical cutaneous changes after topical treatment with nitrogen mustard in patients with mycosis fungoides. Am J Dermatophatol 1996;18:19-23.
5. Abel EA, Sendagorta E, Hoppe RT. Cutaneous malignancies and metastatic squamous cell carcinoma following topical therapies for mycosis fungoides. J Am Acad Dermatol 1986;14:1029-38.
6. Fisher A, Muphree AL, Gomer CJ. Clinical and preclinical photodynamic therapy. Lasers Surg Med 1995;17:2-31.
7. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 1992;14:275-92.
8. Peng Q, Warloe T, Berg K, et al. 5-aminolevulinic acid-based photodynamic therapy. Cancer 1997;79:2282-308.
9. Svanberg K, Anderson T, Killander D, et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-aminolevulinic acid sensitization and laser irradiation. Br J Dermatol 1994;130:743-51.
10. Wolf P, Fink-Puches R, Cerroni L, Kerl H. Photodynamic therapy for mycosis fungoides after topical photosensitization with 5-aminolevulinic acid. J Am Acad Dermatol 1994;31:678-80.
11. Del C Batlle AM. Porphyrins, porphyrias, cancer and photodynamic therapy - a model for cancerogenesis. J Photochem Photobiol B 1993;20:5-22.
12. Malik Z, Lugaci H. Accumulation and translocation of endogenous-porphyrins: their relation to photodynamic destruction of human leukemic cells by photoactivation of endogenous porphyrins. Br J Cancer 1987;56:589-95.
13. Malik Z, Lugaci H. Stimulation of friend erythroleukemic cells cyto-differentiation by 5-aminolevulinic acid; porphyrins, cell size, segregation of sialo-glycoproteins and nuclear translocation. Exp Hematol 1988;16:330-35.
14. Moan J, Bech O, Gaullier JM, et al. Protoporphyrin IX accumulation in cells treated with 5-aminolevulinic acid: dependence on cell density, cell size and cell cycle. Int J Cancer 1998;75:134-9.
15. Malik Z, Halbrecht I, Djaldetti M. Regulation of hemoglobin synthesis, iron metabolism and maturation of friend leukemic cells by 5-aminolevulinic acid and hemin. Differentiation 1979;13:71-9.
16. Eleouet S, Carre J, Vonarx V, Heyman D, Lajat Y, Patrice T. Delta-aminolevulinic acid-induced fluorescence in normal human lymphocytes. J Photochem Photobiol B 1997;41:22-9.
17. Rittenhouse-Diakun K, Van Leengoed H, Morgan J, et al. The role of transferrin receptor (CD71) in photodynamic therapy of activated and malignant lymphocytes using the heme precursor delta-aminolevulinic acid (ALA). Photochem Photobiol 1995;61:523-8.
18. Szeimies RM, Sassy T, Landthaler M. Penetration potency of topical applied aminolevulinic acid for photodynamic therapy of basal cell carcinoma. Photochem Photobiol 1994;59:73-6.
19. Van der Veen N, De Bruijn HS, Berg RJW, Star WM. Kinetics and location of PpIX fluorescence after topical and systemic ALA application, observed in skin and skin tumours of UVB-treated mice. Br J Cancer 1996;73:925-30.
20. Van der Veen N, De Bruijn HS, Star WM. Photobleaching during and re-appearance after photodynamic therapy of topical ALA-induced fluorescence in UVB-treated mouse skin. Int J Cancer 1997;72:110-18.
21. Orenstein A, Kostenich G, Malik Z. The kinetics of protoporphyrin fluorescence during ALA-PDT in human malignant skin tumors. Cancer Lett 1997;120:229-34.
22. Van der Veen N, Van Leengoed HLLM, Star WM. In vivo fluorescence kinetics and photodynamic therapy using 5-aminolevulinic acid-induced porphyrin: increased damage after multiple irradiations. Br J Cancer 1994;70:867-72.
23. Messmann H, Mlkvy P, Buonaccorsi G, Davies CL, MacRobert AJ, Bown SG. Enhancement of photodynamic therapy with 5-aminolaevulinic acid-induced porphyrin photosensitisation in normal rat colon by threshold and light fractionation studies. Br J Cancer 1995;72:589-94.
24. Curnow A, McIlroy BW, Postle-Hacon MJ, MacRobert AJ, Bown SG. Light dose fractionation to enhance photodynamic therapy using 5-aminolevulinic acid in the normal rat colon. Photochem Photobiol 1999;69:71-6.